|
HAYWARD, CA, March 6, 2000 - Sepragen Corporation (OTC BB:
SPGNU, SPGNA, SPGNW) today announced the
formation of a “Techno-Business” advisory board to assist the Company in identifying and developing major
opportunities in the biotech and nutraceutical industries for its platform separation technology.
The advisory board will be headed by Dr. Armin Ramel, formerly Vice President of Research for
Scios, Inc. and
Director of Process Development at Genentech and Hoffman La Roche. The members of the board also include:
- Dr. John Finley, Senior Technology Principal at Kraft Foods, previously Director of New Project
Development at Monsanto and Group Director at Nabisco;
- Dr. Theodore Lioutas, VP of R&D at Brown-Forman Beverages Worldwide, previously Director of New
Product Development at Tropicana;
- Dr. Zdenek Kratky, Senior Advisor and Assistant Vice President for Nutrition Strategic Business
Division at Nestle, Ltd; and
- Dr. H.S. Muralidhar, Assistant VP of R&D and Director of Center of Excellence at Cargill Worldwide.
Vinit Saxena, Sepragen’s Chairman and CEO commented, “Sepragen’s platform separation technology
enables the isolation and manufacture of high purity biological drugs and functional food ingredients
necessary for the development of newer, healthier natural foods and
nutraceuticals. The solutions
provided by these key industry opinion leaders will certainly drive the direction of our growth path. We are
excited about this team and look forward to their contributions.”
Sepragen Corporation develops and markets technology along with equipment and supplies
for process chromatography applications. Sepragen has developed a number of patented
applications that provide large market opportunities in the food and beverage industry,
including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as
well as extracting proteins from whey. The company holds over 14 issued patents relating
to its core technology.
<
Back
The statements in this release that relate to future events
or performance, statements about growth, future regulatory clearances, levels of sales and
market size and future manufacturing capacity and efficiencies are forward-looking
statements that involve risks and uncertainties, including risks associated with
uncertainties related to the development of markets for and commercial acceptance of the
company's products and services, the availability of components, competitors' product
introductions and other risks identified in the company's SEC filings. Actual results may
differ from those described in these forward-looking statements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the
date hereof.
|
